Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	433
Overall Study	STARTED	Mirabegron 25 mg	433
Overall Study	STARTED	Mirabegron 50 mg	440
Overall Study	Safety Analysis Set (SAF)	Placebo	433
Overall Study	Safety Analysis Set (SAF)	Mirabegron 25 mg	432
Overall Study	Safety Analysis Set (SAF)	Mirabegron 50 mg	440
Overall Study	Full Analysis Set (FAS)	Placebo	415
Overall Study	Full Analysis Set (FAS)	Mirabegron 25 mg	410
Overall Study	Full Analysis Set (FAS)	Mirabegron 50 mg	426
Overall Study	Full Analysis Set Incontinence (FAS-I)	Placebo	262
Overall Study	Full Analysis Set Incontinence (FAS-I)	Mirabegron 25 mg	254
Overall Study	Full Analysis Set Incontinence (FAS-I)	Mirabegron 50 mg	257
Overall Study	COMPLETED	Placebo	367
Overall Study	COMPLETED	Mirabegron 25 mg	387
Overall Study	COMPLETED	Mirabegron 50 mg	386
Overall Study	NOT COMPLETED	Placebo	66
Overall Study	NOT COMPLETED	Mirabegron 25 mg	46
Overall Study	NOT COMPLETED	Mirabegron 50 mg	54

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00912964/flow